The Closing 8-K Is a Founder Disclosure Event — What a Public Buyer Will File About Your Deal Within Four Business Days
Selling to a public-company buyer triggers an 8-K filing within four business days of closing. Three things to negotiate at the LOI to manage your own disclosure.
Contingent Value Rights in 2026 Biopharma Take-Privates — What the Triggers Actually Pay, After the $180 Million Syntimmune Ruling
CVRs look like earnouts but Delaware treats them differently. The 2024 Alexion/Syntimmune ruling and the resulting $180 million damages award reset the efforts-standard analysis for biopharma deals.
Florida’s Documentary Stamp Tax on Seller Notes — The Asset-Deal Surprise Buyers Should Price at the LOI
Florida’s documentary stamp tax quietly hits seller notes and secured deal paper. In a Florida asset deal the buyer often discovers it at closing. Three lines at the LOI keep the math from moving.
Reps and Warranties Insurance for Florida Middle-Market M&A: 2026 Pricing, Retention, and When the Premium Earns Its Keep
Florida M&A in 2026: how RWI pricing, retention, and policy structure have shifted, and when middle-market buyers and sellers should pay the premium.
Founder Rollover at the PE Close — Why the F-Reorg Tax Bill Lands Six Months After You Sign
PE buyers sell founder rollover as a tax-free piece of the deal. The F-reorg structure is more complicated than that. Three places the bill lands later, and what to negotiate at the LOI.
The Survival Clause Cannot Bury Fraud — What the 2025 Chancery Line Forces Sellers to Re-Draft
Twelve months of survival looks like the seller’s strongest post-closing shield. The 2025 Delaware Chancery line holds it cannot eliminate fraud claims at all. Three drafting moves the form contract usually misses.
Give us a call at
904-234-5653
or fill out the form below for a consultation.
"*" indicates required fields